Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

Abstract Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including p...

Full description

Bibliographic Details
Main Authors: Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson, Pamela J. Russell
Format: Article
Language:English
Published: SpringerOpen 2020-05-01
Series:EJNMMI Research
Subjects:
Prostate cancer
Radionuclide therapy
Miltuximab®
Glypican-1
MIL-38
Online Access:http://link.springer.com/article/10.1186/s13550-020-00637-x

Internet

http://link.springer.com/article/10.1186/s13550-020-00637-x

Similar Items